Fierce Biotech today published the top 15 sites in the US for biotech venture capital in 2013. This according to figures from the National Venture Capital Association (NVCA) as compiled by Thomas Reuters. The findings are not terribly surprising in terms of the rankings -- except it might be a mild surprise that San Francisco outspent Boston/Cambridge on the VC front last year. Otherwise, the rankings look to make sense. Here is the summary below in terms of place, dollars and numbers of deals. The total dollars for the US was $4.5 B.